n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, July 13th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Innovus Pharmaceuticals, Inc. (INNV)

SeeThruEquityResearch, Promotion Stock Secrets, TopPennyStockMovers, DSR News, Penny Stock Hub, PHUB News, Wall Street Mover, HotTopPennyStocks, PennyPickAlerts, Fortune Stock Alerts, BUYINS.NET, Penny Stock Bets, StockMister, StockMarketQuote.us, Penny Stock Circle, 1-2-3 Stock Alerts, and OTPicks reported earlier on Innovus Pharmaceuticals, Inc. (INNV), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Innovus Pharmaceuticals, Inc. is a developing Over-The-Counter (OTC) consumer goods and specialty pharmaceutical company. It engages in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets its products in the United States and Canada through retailers and on the web. Innovus also details its products to urologists, gynecologists, and sex therapists. It does so either directly in the U.S. or by way of commercial partners internationally. Innovus Pharmaceuticals is based in San Diego, California.

The Company generates revenues from its lead products BTH® Testosterone Booster; BTH® Human Growth Agent; Zestra® for female arousal, and EjectDelay® for premature ejaculation. It has an additional five marketed products. These include Sensum+® for the indication of reduced penile sensitivity; Zestra Glide®; Vesele® for promoting sexual health; RecalMax™ for promoting brain and cognitive health; Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality; BTH Vision Formula; BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if Innovus’ Abbreviated New Drug Application (ANDA) receives approval by the Food and Drug Administration (FDA).

Innovus Pharmaceuticals earlier announced the initiation of a pre-clinical and clinical program intended to evaluate the safety and efficacy of the combination of its supplement Vesele® for promoting sexual health with sildenafil indicated for treating erectile dysfunction. Sildenafil in the U.S. is sold under the name Viagra® by Pfizer, Inc. Vesele® is a proprietary oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine®. Vesele® was formulated to increase blood flow and nitric oxide production.

Recently, Innovus Pharmaceuticals and its partner West-Ward Pharmaceuticals International Limited (WWPIL), a wholly-owned subsidiary of Hikma Pharmaceuticals PLC, announced that WWPIL will provide Innovus with the rights to launch its branded, fluticasone propionate nasal spray USP, 50 mcg per spray (FlutiCare™), under WWPIL’s FDA approved abbreviated new drug application (ANDA) No. 207957, in the U.S. in the second half of this calendar year. FlutiCare™ is the first and only nationally branded OTC product under approved ANDA No. 207957 in the U.S. market.

Innovus also recently announced the launch of AllerVarx™ in the U.S.  AllerVarx™ is a clinically proven supplement, scientifically formulated for the relief of allergy symptoms. AllerVarx™, selling in Europe under the brand name Lertal®, is a product Innovus Pharmaceuticals exclusively in-licensed for the U.S. and Canada from NTC s.r.l. - an Italian company.

Last month, Innovus Pharmaceuticals announced its plans to enter the oncology supportive care OTC market with an exclusive license to two GRAS (Generally Recognized As Safe by the U.S. FDA)-listed compounds, thymol and carvacrol, for cachexia and muscle growth and repair, from the University of Iowa Research Foundation. Precisely, the License is to U.S. Patent Application No. 15/509,438 “Use of Thymol and Carvacrol (monoterpene phenols) for Induction of Increased Skeletal Muscle Endurance, lean Muscle Mass and Reduced Adiposity,” and all related foreign global patent applications.

Innovus Pharmaceuticals, Inc. (INNV), closed Thursday's trading session at $0.1219, down 0.49%, on 101,800 volume with 20 trades. The average volume for the last 60 days is 659,008 and the stock's 52-week low/high is $0.082/$0.663.

Pure Energy Minerals Limited (PEMIF)

InvestorsHub and TradingView reported on Pure Energy Minerals Limited (PEMIF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Pure Energy Minerals Limited engages in the acquisition, exploration, and development of mineral properties. It is a lithium-brine resource developer working to become a low-cost supplier for the growing lithium battery industry. The Company’s flagship lithium brine project is in Clayton Valley, Nevada, immediately contiguous to North America’s only producing lithium mine (Albemarle’s Silver Peak lithium brine mine). Pure Energy Minerals is headquartered in Vancouver, British Columbia.

The Company’s Clayton Valley South (CVS) Project contains an inferred mineral resource of 816,000 tonnes of lithium carbonate equivalent (LCE), reported in accordance with Canadian National Instrument 43-101 on July 28, 2015. The Clayton Valley South Project is in Esmeralda County, Nevada, halfway between Las Vegas and Reno. The Project is a 9,500 Acre Lithium Brine Project.

The Clayton Valley lithium deposit is a salty groundwater (brine). It has high levels of lithium contained in a series of aquifers. Metallurgical and process studies are underway at the Clayton Valley South Project to better understand the feasibility and economics of employing modern environmentally-responsible processing technology to convert the Clayton Valley South brines into high purity lithium products for new energy storage uses.

Pure Energy Minerals is also at the forefront of new processing technologies for lithium. This is via its collaboration with global multinational technology partners including Tenova Bateman (Tenova Bateman Technologies).

In January 2017, Pure Energy Minerals announced that it acquired an option to purchase 100 percent interest in greater than 13,000 hectares (32,000 acres) of prospective lithium brine exploitation concessions on the Pocitos Salar in Salta Province, Argentina. The Properties are positioned in the heart of Argentina’s lithium-rich Puna Region.
 
Pure Energy Minerals announced in March that it closed its acquisition of the purchase option on lithium brine mining concessions in Salta, Argentina announced above. It executed a definitive property purchase agreement under Argentine law with the private owners.

In May, Pure Energy Minerals announced that it closed its earlier announced transactions with Lithium X Energy, GeoXplor, and Clayton Valley Lithium, together with GeoXplor, the “Optionors”) and acquired Lithium X’s interest in 756 unpatented mineral claims encompassing around 15,000 acres (the “LIX Claims”) in Clayton Valley, Nevada. With the addition of the LIX Claims, Pure Energy will have an interest in 1,104 unpatented mineral claims covering roughly 26,000 acres in Esmeralda County, now called the Clayton Valley Lithium Brine Project (CV Project).

Recently, Pure Energy Minerals announced the results of a Preliminary Economic Assessment (PEA) for the production of lithium hydroxide monohydrate from its CV Project. The PEA was prepared jointly by an expert consulting group consisting of of Tenova, Montgomery & Associates, SRK Consulting, and Andeburg Consulting Services, Inc. The PEA forecasts average annual production of about 10,300 tonnes (t) of lithium hydroxide or 9,100 t lithium carbonate equivalent (LCE), employing more efficient and sustainable new technologies, which do not necessitate evaporation ponds.

Yesterday, Pure Energy Minerals announced the commencement of a geophysical exploration program at its Terra Cotta Project (TCP) positioned on the Pocitos Salar in Salta Province, Argentina. The geophysical program consists of a Vertical Electrical Sounding (VES) survey. This includes approximately 75 points at nominal 1-kilometer spacing along five transects. The transects span Pure Energy’s 13,000-hectare mining concession on the Pocitos Salar. Conhidro S.R.L., which is a hydrogeological consultancy headquartered in the city of Salta, Argentina, is performing the work under contract to Pure Energy Minerals.

Pure Energy Minerals Limited (PEMIF), closed Thursday's trading session at $0.421, up 0.41%, on 190,553 volume with 78 trades. The average volume for the last 60 days is 219,456 and the stock's 52-week low/high is $0.36/$0.7359.

Force Protection Video Equipment Corp. (FPVD)

Promotion Stock Secrets, AimHighProfits, and Insider Financial reported previously on Force Protection Video Equipment Corp. (FPVD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Force Protection Video Equipment Corp. sells high definition (HD) body camera systems and accessories for law enforcement. The Company formerly went by the name Enhancer-Your-Reputation.Com, Inc. It changed its corporate name to Force Protection Video Equipment Corp. in March 2015. The Company is based in Cary, North Carolina. Force Protection Video Equipment lists on the OTC Markets Group’s OTCQB.

The Company offers its LE10 Law Enforcement Video Recorder product. The LE10 is a small bodyworn HD camera that is half the size and half the price of most law enforcement cameras presently on the market. The LE10 has numerous features. These include still picture ability 8MP, WIFI, 4x zoom, as well as audio recording. The LE10 does not require special software or expensive storage contracts.

Force Protection has its camera system for Law Enforcement and Security Agencies. The design of the C1, Citadel camera system is to combat and deter graffiti, illegal dumping, and other property crimes. This self-contained system is solar powered. The C1 Citadel can be easily relocated between problem locations and no external power is required. The Citadel Solar Security Camera is ideal for any surveillance application.  

The Company released the LE50 HD Bodycam last year. The LE50 is a state-of-the-art designed body camera. It is strategically built around Ambarella chip sets (AMBA).

Important design features of the LE50 include industry leading record time (10 hours @1080,12 hours @720); 50 hours of standby time; 32GB of internal tamperproof storage; and white LED illumination. Additionally, important design features include audio announcements; GPS recording; 30 second pre-and post-record; and integration with VeriPic© Evidence Management Software. Force Protection Video Equipment has received FCC, IC and CE certification for the LE50 HD on the body video recorder.

Force Protection has also released the LE100 and LE101 1080 HD in car video recording dashcam systems. The LE100 and 101 are state-of-the-art designed in-car dash camera systems strategically built around Ambarella A7 chip sets (AMBA).

In June, Force Protection Video Equipment announced that the Amsterdam Police began implementing the LE50 HD body cameras for evaluation. These cameras were sold by Force’s exclusive European distributor.

Mr. Paul Feldman, Force Protection Video Equipment’s Chief Executive Officer, stated, "We are hopeful the successful implementation of the LE50 by the Amsterdam Police is the first step in our international marketing of the Force Protection Body camera systems.”

Force Protection Video Equipment Corp. (FPVD), closed Thursday's trading session at $0.0198, down 11.21%, on 25,204 volume with 4 trades. The average volume for the last 60 days is 118,068 and the stock's 52-week low/high is $0.0148/$24.975.

Sun BioPharma, Inc. (SNBP)

AllPennyStocks, TheStockWizards.net, The Dean, FeedBlitz, MicrocapVoice, Today's Financial News, HotPennyStocksNow, OTC Picks, Hot Shot Stocks, Wall Street Resources, Beacon Equity Research, Greenbackers, CoolPennyStocks, AheadoftheBulls, Otcstockexchange, HotOTC, and Lebed.biz reported on Sun BioPharma, Inc. (SNBP), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Sun BioPharma, Inc. is a biopharmaceutical company listed on the OTC Markets Group’s OTCQB. It is developing disruptive therapeutics for the treatment of patients with pancreatic diseases. A clinical-stage biopharmaceutical company, Sun BioPharma’s development programs target diseases of the pancreas, including pancreatic cancer and pancreatitis. Sun BioPharma is based in Waconia, Minnesota.

The Company’s initial product candidate is SBP-101. This product is for the treatment of patients with pancreatic cancer. Mr. Ray Bergeron, Ph.D. Distinguished Professor Emeritus, University of Florida. invented SBP-101. Sun BioPharma’s intention is to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, which is the most common kind of pancreatic cancer.

SBP-101 is a first-in-class, proprietary, polyamine compound. The design of it is to exert therapeutic effects in a mechanism specific to the pancreas. The Company originally licensed SBP-101 from the University of Florida in 2011.

The molecule has been shown to be highly effective in human pancreatic cancer models. It has demonstrated superior activity to existing Food and Drug Administration (FDA) approved chemotherapy agents. Moreover, combination therapy potential has been shown for pancreatic cancer.

In addition, Sun BioPharma’s SBP-102 is now in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. Furthermore, the Company’s SBP-103 is now in non-clinical exploratory evaluation.

Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, California; the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia, and the Ashford Cancer Centre in Adelaide, Australia.  

Last month, Sun BioPharma announced completion of the fifth patient cohort in the dose-escalation phase of its Phase 1 clinical study using SBP-101 to treat patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDA). After review of the fifth cohort patients by the Data Safety Monitoring Board (DSMB) it has been determined to dose the next cohort at a lower dose level to approach the Maximum Tolerated Dose (MTD) of SBP-101.

Based on Sun BioPharma analysis of the safety and efficacy data from 25 patients in Cohorts 1-5, direction from the DSMB and per the approved protocol for this Phase 1a study, the next cohort of patients will comprise three patients treated at the same dose level of Cohort 4. Patients are now being recruited for this next cohort. One patient has completed the first cycle of dosing. The expectation is that this cohort of patients will be completed by next month.

Sun BioPharma, Inc. (SNBP), closed Thursday's trading session at $1.25, even for the day. The average volume for the last 60 days is 3,483 and the stock's 52-week low/high is $0.55/$4.50.

Esports Entertainment Group, Inc. (GMBL)

Real Pennies reported earlier on Esports Entertainment Group, Inc. (GMBL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Esports Entertainment Group, Inc. is a next generation, licensed, online gambling enterprise specifically centered on eSports wagering. Its intention is to offer wagering on eSports events in a fully licensed, regulated, and secured platform to the global eSports audience, excluding the United States.  A team of industry and technical experts from the online gambling and video game industries, and e-Sports, marketing, legal, and financial professionals lead Esports Entertainment Group. Esports Entertainment Group has offices in St. Mary's, Antigua and Barbuda.

In addition, the Company’s intention is to offer users around the world the ability to participate in multi-player video games tournaments online for cash prizes. Presently, Esports Entertainment Group is developing several play money websites and its real money wagering website.

The Company has been issued a Client Provider Authorization Permit by the Kahnawake Gaming Commission. Esports Entertainment Group has applied for an Interactive Wagering License with the Financial Services Regulatory Commission of Antigua and Barbuda to conduct real money interactive gaming on an international basis from centers in Canada and Antigua.

Esports has entered into a Betting Gaming Platform Software Agreement with Swiss Interactive Software GmbH to provide wagering platform software. Also, the Company has an agreement with CAMS, LLC to provide global electronic payment and risk management solutions. Esports Entertainment Group has a peer-to-peer wagering system. It will offer real money betting exchange style wagering on all professional eSports events.

Recently, Esports Entertainment Group announced the closing of its earlier announced financing, for total proceeds of $1,200,000. Proceeds of the financing will be used to launch the Company’s online Esports gambling platform that will be fully licensed and the highest regulated esports gambling site worldwide. Further to the launch of its platform, proceeds from the financing will be used to execute its business development strategy for the remainder of the year. This includes exhibiting at the world's largest esports conferences in the coming months.

Last month, Esports Entertainment announced the hiring of key personnel, staff, as well as the opening of its Antigua office in preparation for the pending launch of its Esports betting operations. Regarding its Digital Marketing Team, the Company announced the hiring of two digital marketing experts: Mr. Stephen Banham - Social Media Marketing Manager; and Ms. Sandra Österlund - Global Affiliate Manager. Mr. Banham has served as a Social Media Marketing Consultant and Manager in the gaming industry since 2012. Ms. Österlund has served as an Affiliate Marketing Manager and Marketing Executive to a number of online casinos and eGaming Operators.

Esports Entertainment Group, Inc. (GMBL), closed Thursday's trading session at $1.60, up 18.52%, on 11,691 volume with 37 trades. The average volume for the last 60 days is 1,731 and the stock's 52-week low/high is $0.051/$2.00.

graphic

The QualityStocks
Company Corner

graphic
graphic

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.26, even or the day, on 204,388 volume with 119 trades. The stock’s average daily volume over the past 60 days is 524,838, and its 52-week low/high is $0.05/$0.72.

CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article covering InMed Pharmaceuticals Inc.'s new research and development deal with ATERA SAS of France and the company's development of INM-750 for the treatment of epidermolysis bullosa (EB).

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

InMed Signs R&D Agreement with ATERA

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0193, off by 1.03%, on 6,671,552 volume with 197 trades. The stock’s average daily volume over the past 60 days is 6,812,124, and its 52-week low/high is $0.0075/$0.142.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of NNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication is entitled, "What it Takes to Stand Out from the Crowd in the Legalized Marijuana Space." It highlights multiple publicly traded companies in the marijuana sector, and what these unique contenders are doing to stand out. To view the full publication visit: https://www.networknewswire.com/takes-stand-crowd-legalized-marijuana-space/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Discussing Emerging Standouts in the Legalized Marijuana Sector

What it takes to Stand Out from the Crowd in the Legalized Marijuana Space

SinglePoint Signs Deal to Manufacture CBD Hemp Oil Patches -- CFN Media

Converde Energy USA, Inc. (XFUL)

The QualityStocks Daily Newsletter would like to spotlight Converde Energy USA, Inc. (XFUL). Today, Converde Energy USA, Inc. closed trading at $0.0031, off by 3.12%, on 228,059 volume with 12 trades. The stock’s average daily volume over the past 60 days is 1,557,749, and its 52-week low/high is $0.0002/$0.10.

Multifaceted financial news and publishing company NetworkNewsWire (“NNW”) this morning announced the online availability of an exclusive audio interview with diversified energy company Converde Energy USA (OTC: XFUL), doing business as American Energy Partners, Inc. In the interview, Josh C. Hickman, president of the company’s Gilbert Oil & Gas, LLC, subsidiary, gives listeners insight into XFUL’s corporate history, as well as its ongoing efforts to capitalize on growing markets, such as the market for water ownership. The full interview can be heard at http://nnw.fm/ZG3pQ. To view the full press release, visit: http://nnw.fm/zQ1cL

Converde Energy USA, Inc. (XFUL), d/b/a American Energy Partners Inc., and its group of companies are dedicated to delivering solutions wherever energy production and water meet technology. The company has positioned itself to benefit from above-favorable margins on each of its subsidiaries due to the synergy of the chain of revenues.

Hydration Company of PA (HCPA)
Hydration Company of PA focuses on sourcing, implementing and distributing reclaimed water at a profit. This subsidiary's competitive advantage mainly lies within its pure volume of reclaimed water and its access to low cost treatment with high flow rates and highly concentrated solids through the technologies of XFUL's partners. Because of the volume as well as the flexibility of the model established via patent pending methodology and conveyance methods, HCPA can effectively gain market share immediately as large corporations prefer access to one source that can supply massive amounts of reclaimed water regardless of drought conditions.

American Energy Solutions, LLC
American Energy Solutions, LLC utilizes a network of partners to provide off-the-shelf and custom-designed treatment technologies that contribute to HCPA's business model of low-cost treatment and distribution. As a provider of design, this subsidiary is capable of repeatable and synergistic services across the value chain. American Energy's long-term plan is to utilize an in-house team to grow market share as water use continues to become more critical to modern industry.

Gilbert Oil & Gas Company
Gilbert Oil & Gas Company is leveraging broad industry valuation experience to move forward on its mission to add shareholder value through drilling, operating, and partnership opportunities in the upstream oil and gas space. Equipped with the in-house capabilities necessary to source and evaluate opportunities for profitability, Gilbert is positioned to become a strong customer of XFUL's other subsidiaries, providing them with the foundation to attract other customers and enter new markets.

Integrated Business Strategy
By combining ownership of water sources via Hydration Company of PA, design and treatment solutions via American Energy Solutions, and a stream of promising opportunities via Gilbert Oil & Gas Company, XFUL is essentially creating a positive revenue feedback loop. This synergistic business model also opens opportunity for higher profit margins, additional revenue, and faster growth in new markets. Disclaimer

Converde Energy USA, Inc. Company Blog

Converde Energy USA, Inc. News:

NetworkNewsBreaks – American Energy Partners, Inc. (XFUL) Featured in Exclusive Audio Interview by NetworkNewsWire

Converde Energy USA, Inc. Appoints Josh Hickman, President of Subsidiary's O&G Operations and to Board of Directors

American Energy Partners, Inc. (XFUL) d/b/a Converde Energy USA, Inc. Engages NetworkNewsWire for Corporate Communications Solutions

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.01, up 25.00%, on 78,200 volume with 11 trades. The stock’s average daily volume over the past 60 days is 77,474, and its 52-week low/high is $0.0061/$0.09.

Epazz, Inc. (EPAZ), is an enterprise-wide software company specializing in customized web applications for higher education institutions and the public sector. Through its proprietary BoxesOS applications, the company aims to create and maintain virtual communities that facilitate enhanced communication and provide up-to-date information and content in order to streamline the decision-making process for its clients. Epazz's BoxesOS also serves as a secure digital marketplace for various types of commerce, allowing the company to meet the increasing information technology demands of the 21st century.

In addition to its BoxesOS administrative services, Epazz offers a full end-user suite of solutions designed to maximize communication and functionality with full-featured web-based intranet software. Leveraging these offerings, the company's clients gain secure access and administrative control to customized features based on their unique needs. For businesses, the value of implementing these services can be tremendous. According to data from the McKinsey Global Institute, productivity improves by as much as 25 percent in organizations with connected employees. Studying just four commercial sectors (consumer packaged goods, retail financial services, advanced manufacturing and professional services), McKinsey estimates that the fiscal contributions of implementing effective intranet solutions could amount to as much as $1.3 trillion annually.

BoxesOS also allows companies to enhance communications with stakeholders by providing one-stop access to elegant, web-enabled information dashboards designed for specific user groups. Offering the ability to create unique dashboards for each stakeholder group addresses one of the most prominent issues facing workplace intranet projects – lack of engagement. Industry data suggest that properly engaging three core types of stakeholders, including executives, implementers and users, as well as the many sub-types within each of those groups, is key to the successful implementation of digital workplace solutions.

Outside of its business software solutions, Epazz is currently addressing a rising demand in the legal cannabis industry through its ZenaPay payment system. While banks remain hesitant regarding the legality of state-approved cannabis programs, dispensaries and related businesses have been compelled to operate on a cash-only basis, creating both security concerns and inconvenience for their customers. With ZenaPay, Epazz seeks to eliminate this issue by relying on the widely-used bitcoin cryptocurrency to provide an alternative to cash transactions. These efforts are particularly intriguing when studying the forward projections associated with marijuana sales. Per ArcView Market Research, North American marijuana sales grew by an unprecedented 30 percent in 2016 to $6.7 billion, and this figure is expected to top $20.2 billion by 2021.

Epazz is led by founder, chairman and CEO Shaun Passley, Ph.D. Founding the company in February 1999, Passley has been the guiding force behind Epazz's software and product development, as well as its continuing development of future products and services. Passley is joined on the Epazz management team by Raymond Kennedy, director of sales. Kennedy has more than two decades of experience in enterprise software sales, having previously served as marketing director for HCM, Inc., where he established six new sales territories and increased overall sales by more than 30 percent. Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz, Inc. Featured on MoneyTV with Donald Baillargeon, 6/2

Epazz, Inc. Reports Increase First Quarter Revenue and Profitability; Company is Focusing on Improving Fundamentals; Increasing Sales, Reducing Operational Expenses and Increasing Income

Epazz, Inc. Launches Zenapay.com, the Company's New Cannabis Payment System

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.09, even with yesterday's close. The stock’s average daily volume over the past 60 days is 10,365 and its 52-week low/high is $0.0001/$0.65.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

Algae Dynamics Corp Announces Engagement of Atlanta-Based Broker Dealer Carter, Terry & Company

Algae Dynamics Corp Announces Memorandum Of Understanding With Bonify for Supply of Cannabis, Oil Extraction and Sales

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(IDDR) +46.20%

2.

Wall Street Mover
(YUMA) +41.13%

3.

StockMarketWatch
(XGTI) +23.57%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251